Discussion on the indication of allogeneic stem cell transplantation for advanced cutaneous T cell lymphomas

Silvana Novelli; Anna Monter; M. Pilar García-Muret; Rodrigo Martino; Javier Briones; Jorge Sierra

doi:10.1007/s12185-019-02707-w

Discussion on the indication of allogeneic stem cell transplantation for advanced cutaneous T cell lymphomas

Silvana Novelli, Anna Monter, M. Pilar García-Muret, Rodrigo Martino, Javier Briones, Jorge Sierra

Department of Medicine

Research output: Contribution to journal › Review article › Research › peer-review

2 Citations (Scopus)

Abstract

© 2019, Japanese Society of Hematology. Advanced cutaneous T cell lymphoma (CTCL) patients have a dismal prognosis, especially those relapsing or progressing after systemic therapy. No curative therapies are available, but some new agents have prolonged disease-free survival time with a good toxicity profile. Allogeneic stem cell transplantation (allo-SCT) offers the longest disease-free survival, potentially representing the best therapeutic option for eligible patients. In the present article, we discuss current evidence about allo-SCT for CTCL patients, timing, and new therapeutic options before allo-SCT, taking into account some considerations that may impact clinical outcome.

Original language	English
Pages (from-to)	406-410
Journal	International Journal of Hematology
Volume	110
Issue number	4
DOIs	https://doi.org/10.1007/s12185-019-02707-w
Publication status	Published - 1 Oct 2019

Keywords

Allogeneic hematopoietic transplantation
Cutaneous T cell lymphoma
Mycosis fungoide
Sézary syndrome

Access to Document

10.1007/s12185-019-02707-w

Cite this

@article{61f348f15382499abdbbbfe1d18612f1,

title = "Discussion on the indication of allogeneic stem cell transplantation for advanced cutaneous T cell lymphomas",

abstract = "{\textcopyright} 2019, Japanese Society of Hematology. Advanced cutaneous T cell lymphoma (CTCL) patients have a dismal prognosis, especially those relapsing or progressing after systemic therapy. No curative therapies are available, but some new agents have prolonged disease-free survival time with a good toxicity profile. Allogeneic stem cell transplantation (allo-SCT) offers the longest disease-free survival, potentially representing the best therapeutic option for eligible patients. In the present article, we discuss current evidence about allo-SCT for CTCL patients, timing, and new therapeutic options before allo-SCT, taking into account some considerations that may impact clinical outcome.",

keywords = "Allogeneic hematopoietic transplantation, Cutaneous T cell lymphoma, Mycosis fungoide, S{\'e}zary syndrome",

author = "Silvana Novelli and Anna Monter and {Pilar Garc{\'i}a-Muret}, M. and Rodrigo Martino and Javier Briones and Jorge Sierra",

year = "2019",

month = oct,

day = "1",

doi = "10.1007/s12185-019-02707-w",

language = "English",

volume = "110",

pages = "406--410",

journal = "International Journal of Hematology",

issn = "0925-5710",

number = "4",

}

TY - JOUR

T1 - Discussion on the indication of allogeneic stem cell transplantation for advanced cutaneous T cell lymphomas

AU - Novelli, Silvana

AU - Monter, Anna

AU - Pilar García-Muret, M.

AU - Martino, Rodrigo

AU - Briones, Javier

AU - Sierra, Jorge

PY - 2019/10/1

Y1 - 2019/10/1

N2 - © 2019, Japanese Society of Hematology. Advanced cutaneous T cell lymphoma (CTCL) patients have a dismal prognosis, especially those relapsing or progressing after systemic therapy. No curative therapies are available, but some new agents have prolonged disease-free survival time with a good toxicity profile. Allogeneic stem cell transplantation (allo-SCT) offers the longest disease-free survival, potentially representing the best therapeutic option for eligible patients. In the present article, we discuss current evidence about allo-SCT for CTCL patients, timing, and new therapeutic options before allo-SCT, taking into account some considerations that may impact clinical outcome.

AB - © 2019, Japanese Society of Hematology. Advanced cutaneous T cell lymphoma (CTCL) patients have a dismal prognosis, especially those relapsing or progressing after systemic therapy. No curative therapies are available, but some new agents have prolonged disease-free survival time with a good toxicity profile. Allogeneic stem cell transplantation (allo-SCT) offers the longest disease-free survival, potentially representing the best therapeutic option for eligible patients. In the present article, we discuss current evidence about allo-SCT for CTCL patients, timing, and new therapeutic options before allo-SCT, taking into account some considerations that may impact clinical outcome.

KW - Allogeneic hematopoietic transplantation

KW - Cutaneous T cell lymphoma

KW - Mycosis fungoide

KW - Sézary syndrome

UR - http://www.mendeley.com/research/discussion-indication-allogeneic-stem-cell-transplantation-advanced-cutaneous-t-cell-lymphomas

U2 - 10.1007/s12185-019-02707-w

DO - 10.1007/s12185-019-02707-w

M3 - Review article

C2 - 31317515

SN - 0925-5710

VL - 110

SP - 406

EP - 410

JO - International Journal of Hematology

JF - International Journal of Hematology

IS - 4

ER -

Discussion on the indication of allogeneic stem cell transplantation for advanced cutaneous T cell lymphomas

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this